Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. BioMarin Pharmaceuticals, Inc.
483
•BioMarin Pharmaceuticals, Inc.•September 24, 2013

BioMarin Pharmaceuticals, Inc. – FDA 483, Sep 24, 2013

Record Details

An FDA Form 483 was issued to Jeiovarin maraceuticale, tac. following an inspection conducted from September 16 to September 24, 2013. The primary observation highlighted a failure to ensure proper monitoring of a clinical study. Specifically, the company's contract research organization (CRO) was found to have inadequately reviewed and verified case report forms and source documents for a study subject. This oversight led to a critical error where a discrepancy in the subject's reported weight resulted in an overdose of the study drug during weeks 5 through 8 of the clinical trial. These observations signify potential non-compliance with regulatory expectations for clinical trial oversight, which mandate rigorous monitoring to safeguard patient safety and data integrity. While the document itself details the observation, an FDA 483 typically requires the inspected firm to thoroughly investigate the identified issues, propose comprehensive corrective actions to address the deficiencies, and implement preventive measures to avoid recurrence. Such actions are crucial to uphold patient welfare and ensure the reliability of clinical trial data, aligning with the regulatory framework governing pharmaceutical research.

Company
BioMarin Pharmaceuticals, Inc.
Inspection date
September 24, 2013
Product type
drugs
Office
San Francisco District Office
People
  • Andrej Gasperlin, President
  • Aneel K. Sandhu (Government Employee)
View Company Profile

ID · c6225f0a-c847-4175-aca8-8e0609be02a9

Other documents for BioMarin Pharmaceuticals, Inc.
  • 483 - 2024-12-13December 13, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BioMarin Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.